##plugins.themes.academic_pro.article.sidebar##

Download
pdf
Statistic
Read Counter : 91 Download : 75

##plugins.themes.academic_pro.article.main##

Abstract

Despite cancer therapeutics-related cardiac dysfunction (CTRCD) can be initially asymptomatic, if not detected and properly managed, it may progress to severe and irreversible heart failure. Therefore, identification of high-risk patients and early detection of subclinical myocardial dysfunction are fundamental tasks for the management of cancer patients undergoing chemotherapy, involving both cardiologists and oncologists. LVEF has low sensitivity for the detection of small changes in LV function. LVEF calculated by conventional 2DE often fails to detect small changes in LV contractility because of several factors. These factors include LV geometric assumptions, inadequate visualization of the true LV apex, lack of consideration of subtle regional wall motion abnormalities, and inherent variability of the measurement. Accordingly, strategies using newer echocardiographic technology, such as STE-derived strain imaging for the early detection of subclinical LV systolic dysfunction. GLS being the most robust and reproducible among the myocardial strain parameters, this parameter has raised the interest of the investigators to detect early and subclinical myocardial dysfunction in patients at risk of CTCRD

Keywords

detected patients parameters subclinical

##plugins.themes.academic_pro.article.details##

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

How to Cite
Dr. Firas Yahya Ibrahim, Prof. Hasan Farhan, & Prof. Ali Mohameed Jawad. (2024). Echocardiographic Assessment of Left Ventricular Systolic Function in Lymphoma Patient After Initial Dose of Chemotherapy in Baghdad Teaching Hospital. Texas Journal of Medical Science, 28, 48–59. https://doi.org/10.62480/tjms.2024.vol28.pp48-59
Crossref
Scopus
Google Scholar
Europe PMC

References

  1. Khouri MG, Douglas PS, Mackey JR, et al. Cancer therapy-induced cardiac toxicity in early breast cancer: addressing the unresolved issues. Circulation 2012;126:2749-63.
  2. Witteles, Ronald M., Fowler, Michael B.,et al. Chemotherapy-Associated Cardiotoxicity: How Often Does it Really Occur and How Can it Be Prevented? Heart Failure Clinics.2011; volume 7, issue 3 .
  3. Ewer MS, Ewer SM. Long-term cardiac safety of dose-dense anthracycline therapy cannot be predicted from early ejection fraction data. J Clin Oncol 2009;27:6073-5.
  4. Kapusta L, Thijssen JM, Groot-Loonen J, et al. Tissue Doppler imaging in detection of myocardial dysfunction in survivors of childhood cancer treated with anthracyclines. Ultrasound Med Biol 2000;26:1099-108.
  5. Cardinale D, Colombo A, Lamantia G, et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. JAmCollCardiol 2010;55:213-20.
  6. Ho E, Brown A, Barrett P, et al. Subclinical anthracycline- and trastuzumab-induced cardiotoxicity in the long-term follow-up of asymptomatic breast cancer survivors: a speckle tracking echocardiographic study. Heart 2010;96:701-7.
  7. Nagy AC, Cserep Z, Tolnay E,et al. Early diagnosis of chemotherapy-induced cardiomyopathy: a prospective tissue Doppler imaging study. Pathol Oncol Res 2008;14:69-77.
  8. Aurigemma GP. Quantitative evaluation of left ventricular structure, wall stress and systolic function. Catherine M. Otto, editor. The Practice of Clinical Echocardiography, sixth ed. 2018, Philadelphia: Elsevier.
  9. Mor-Avi V, Lang RM, Badano LP, et al: Current and evolving echocardiographic techniques for the quantitative evaluation of cardiac mechanics: ASE/EAE consensus statement on methodology and indications endorsed by the Japanese Society of Echocardiography, J Am Soc Echocardiogr.2011; 24(3):277–313.
  10. Rydberg E, Arlbrandt M, Gudmundsson P,et al.Left atria- ventricular plane displacement predicts cardiac mortality in patients with chronic atrial fibrillation. Int. J. Cardiol. 2003; 91: 1–7.
  11. Armstrong, William F., Ryan, Thomas. Evaluation of Systolic Function of the Left Ventricle. Ryan, Thomas, Edit. Feigenbaum's Echocardiography. 8th Edition. 2019, Wolters Kluwer.
  12. Scott D. Solomon, Bernard E. Bulwer. Echocardiographic Assessment of Ventricular Systolic Function. Solomon, Justina, Gillam, Edit. ESSENTIAL ECHOCARDIOGRAPHY. 10th edition. 2019, Philadelphia, Elsevier.
  13. Juan Carlos Plana, Maurizio Galderisi, Ana Barac , et al. Expert Consensus for Multimodality Imaging Evaluation of Adult Patients during and after Cancer Therapy: A Report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2014; 27:911-39.
  14. Cardinale D, Sandri MT, Colombo A, et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 2004;109(22):2749–54.
  15. Cardinale D, Sandri MT. Role of biomarkers in chemotherapy-induced cardiotoxicity. Prog Cardiovasc Dis 2010;53:121-9.
  16. Reichlin T, Hochholzer W, Bassetti S, et al. Early diagnosis of myocardial infarction with sensitive cardiac troponin assays. N Engl J Med 2009;361:858-67.
  17. Hidekazu Tanaka. Echocardiography and cancer therapeutics‑related cardiac Dysfunction. Journal of Medical Ultrasonics.2019; 46: pages309–316.
  18. Edward G. Brooks, Joseph M., Laurie H. et al. Impact of Time from Diagnosis to Initiation of Curative-Intent Chemotherapy on Clinical Outcomes in Patients with Hodgkin Lymphoma. Blood (2013) 122 (21): 4237.
  19. Yali Xu , Joerg Herrmann, Patricia A Pellikka, et al. Early Changes in 2D-Speckle-Tracking Echocardiography May Predict a Decrease in Left Ventricular Ejection Fraction in Lymphoma Patients Undergoing Anthracycline Chemotherapy: A Pilot Study. J Clin Exp Oncol.2015; Vol: 4 Issue:1.
  20. Sadeq I A, Mohammed Q M, Hussein A A, et al. Detection of Subclinical Left Ventricular Systolic Dysfunction in Patient Treated with Anthracycline Chemotherapy: A Comparative Analysis Between Different LV Systolic Echocardiographic Parameters. Int. J. Adv. Res. Biol. Sci. (2019). 6(8): 137-147.
  21. Joanna Luszczak*, Maria Olszowska, Sylwia Drapisz,et al. Assessment of left ventricle function in aortic stenosis: mitral annular plane systolic excursion is not inferior to speckle tracking echocardiography derived global longitudinal peak strain. Cardiovascular Ultrasound 2013, 11:45.
  22. JACOPO OLIVIERI, GIAN PIERO PERNA, CATERINA BOCCI, et al. Modern Management of Anthracycline-Induced Cardiotoxicity in Lymphoma Patients: Low Occurrence of Cardiotoxicity with Comprehensive Assessment and Tailored Substitution by Nonpegylated Liposomal Doxorubicin. TheOncologist 2017;22:422–431.
  23. Ines Monte, Vera Elena Bottari, Sergio Buccheri,et al. Chemotherapy-Induced Cardiotoxicity: Subclinical Cardiac Dysfunction Evidence Using Speckle Tracking Echocardiography. J Cardiovasc Echogr. 2013 Jan-Mar; 23(1): 33–38.
  24. M Lotrionte 1, G Palazzoni, R Natali, G Comerci, et al. Assessment of Left Ventricular Systolic Dysfunction by Tissue Doppler Imaging to Detect Subclinical Cardiomyopathy Early After Anthracycline Therapy. Minerva Cardioangiol. 2007 Dec;55(6):711-20.
  25. S. Limat, Pharm D,E. Daguindau, et al. Incidence and risk-factors of CHOP/R-CHOP-related cardiotoxicity in patients with aggressive non-Hodgkin’s lymphoma. Journal of Clinical Pharmacy and Therapeutics, 2014; 39: 168–174.
  26. Tomoko Negishi 1, Paaladinesh Thavendiranathan 2, Kazuaki Negishi 1, et al. Rationale and Design of the Strain Surveillance of Chemotherapy for Improving Cardiovascular Outcomes: The SUCCOUR Trial. JACC Cardiovasc Imaging 2018 Aug;11(8):1098-1105.